Uniphar (DUB:UPR) YoY EBITDA Growth: -14.60% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DUB:UPR Uniphar PLC DUB:UPR
71 GF Score
Price €4.30
GF Value €3.68
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Uniphar YoY EBITDA Growth?

Uniphar DUB:UPR -0.70% 71 YoY EBITDA Growth is -14.60% as of Dec. 2025. GuruFocus rates DUB:UPR with a GF Score™ of 71/100 and a GF Value™ of €3.68 (Modestly Overvalued). The stock has 4 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Uniphar's YoY EBITDA Growth for the quarter that ended in Dec. 2025 was -14.60%.

Uniphar's EBITDA per Share for the six months ended in Dec. 2025 was €0.27.

Uniphar YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Uniphar's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Uniphar YoY EBITDA Growth Chart

Uniphar Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 41.88 4.52 19.31 21.01 -8.58

Uniphar Semi-Annual Data
Dec16 Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.63 8.77 30.17 2.15 -14.60
DUB:UPR
71GF Score
Uniphar PLC DUB:UPR
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Uniphar YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Uniphar's YoY EBITDA Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (A: Dec. 2025 )
=(EBITDA per Share (A: Dec. 2025 )-EBITDA per Share (A: Dec. 2024 ))/ | EBITDA per Share (A: Dec. 2024 ) |
=(0.458-0.501)/ | 0.501 |
=-8.58 %

Uniphar's YoY EBITDA Growth for the quarter that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (Q: Dec. 2025 )
=(EBITDA per Share (Q: Dec. 2025 )-EBITDA per Share (Q: Dec. 2024 )) / | EBITDA per Share (Q: Dec. 2024 )) |
=(0.269-0.315)/ | 0.315 |
=-14.60 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of -14.60% mean?
Uniphar (DUB:UPR) has a YoY EBITDA Growth of -14.60% as of Dec. 2025. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Uniphar and its competitors.
Is Uniphar's YoY EBITDA Growth too high?
Uniphar's current YoY EBITDA Growth is -14.60%. Overall, Uniphar has a GF Score™ of 71/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Uniphar's YoY EBITDA Growth compare to MCK and COR?
Uniphar's YoY EBITDA Growth of -14.60% can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Medical Distribution company?
A good YoY EBITDA Growth depends on the Medical Distribution industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Uniphar and its competitors. Uniphar's current YoY EBITDA Growth is -14.60%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Uniphar stock overvalued right now?
Based on GuruFocus' analysis, Uniphar (DUB:UPR) is currently considered Modestly Overvalued. The stock's GF Value™ is €3.68, compared to a current price of €4.30 — trading 16.8% above its estimated fair value. The current YoY EBITDA Growth is -14.60%. Uniphar's overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Uniphar (DUB:UPR), the current YoY EBITDA Growth is -14.60% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Uniphar (DUB:UPR) Overvalued in 2026?

Based on GuruFocus' analysis, Uniphar stock appears to be overvalued. The current stock price of €4.30 is trading 16.8% above its estimated GF Value™ of €3.68. GuruFocus considers Uniphar to be Modestly Overvalued.

Key valuation signals for DUB:UPR:

  • YoY EBITDA Growth: -14.60%
  • GF Value™: €3.68 vs. price of €4.30 (16.8% above fair value)
  • GF Score™: 71/100 with 4 warning signs

No single metric tells the full story. See the DUB:UPR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Uniphar Business Description

Other Exchanges UPR:UK0NR:Germany
Address 4045 Kingswood Road, Citywest Business Park, Dublin, IRL, D24 V06K
Uniphar PLC is a service provider within the pharmaceutical and healthcare sector. The company is an international diversified healthcare services business servicing the requirements of multinational pharmaceutical and medical technology manufacturers across three divisions - Uniphar Pharma, Uniphar Medtech and Uniphar Supply Chain & Retail. Uniphar Pharma enables pharma and biotech companies to bring medicines to markets globally and provide healthcare professionals with access to medicines that can't be sourced through traditional channels. Uniphar Medtech is a Pan-European medical device distributor and solutions partner. Uniphar Supply Chain & Retail is the pharmaceutical wholesaler in Ireland offering of retail pharmacies.
71GF Score

Get the complete analysis for DUB:UPR

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.30
Price
€3.68
GF Value